Tissue Regenix, the Leeds-based regenerative medical devices firm, reported a six per cent decline in group revenue to $13.8m/£10.2m for the six months ending 30 June 2025, compared with $14.7m/£10.9m in H1 2024.
The drop reflects lower orders from strategic partners amid ongoing economic uncertainty. The company’s BioRinse portfolio fell to $9.8m/£7.3m from $10.5m/£7.8m a year earlier, affected by partner order reductions and delays in regulatory approvals that have slowed market expansion.
dCELL® sales, driven by the DermaPure® line, decreased four per cent year-on-year to $4m/£3m due to weaker partner demand. Direct distribution channels, however, grew revenue by 10 per cent, supported by the addition of 32 new distributors in the first half of 2025.
Tissue Regenix expects a positive adjusted EBITDA for H1 2025 and maintains guidance for full-year adjusted EBITDA profitability at levels comparable with FY 2024. The company reports a cash position sufficient to fund its organic growth strategy and planned expansion into 2026.
Leadership changes have been confirmed. Jay LeCoque joins as executive chairman, bringing more than 25 years of experience in global life sciences business development. Jonathan Glenn and Trevor Phillips have resigned from the board, effective immediately.
